BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter

BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter

BioMarin Pharmaceutical (NASDAQ: BMRN) turned in a second-quarter report on Wednesday that showed it continuing to grow sales of its current drugs, getting new drugs approved, and producing promising clinical trial data on its pipeline candidates. There isn't much else investors in biotechs can ask for.

Metric

Q2 2017

Continue reading

Source: Fool.com